

10/4/30

DIALOG(R) File 351:Derwent WPI

(c) 2001 Derwent Info Ltd. All rts. reserv.

AA- 1993-391675/199349 |

XR- <XRAM> C93-173796|

TI- Chocolate compsn. effective against **thrombosis** and **atherosclerosis**
contg. fat including eicosa-pentaenoic acid and/or docosa-hexaenoic
acid and **catechin** |

PA- ASAHI DENKA KOGYO KK (ASAE)|

NC- 001|

NP- 001|

PN- JP 5292885 A 19931109 JP 92103276 A 19920422 199349 B|

AN- <LOCAL> JP 92103276 A 19920422|

AN- <PR> JP 92103276 A 19920422|

FD- JP 5292885 A A23G-001/00|

LA- JP 5292885(10)|

AB- <BASIC> JP 5292885 A

A chocolate compn. comprises a non-hydrogenated fat and oil
containing eicosapentaenoic acid (EPA) and/or docosahexaenoic acid
(DHA) and a **catechin** .

Pref. fats and oils contain DHA and/or EPA in 5-50 (7-40) w/w%.
Fats and oils are eg. fish oil, whale oil, cod-liver oil, shell oil,
bacterial oil, etc. The composition contains the fats and oils in 1-10
w/w %, pref. 2-5 w/w %. The **catechin** includes **gallocatechin** ,
epigallocatechin , **epicatechin** , **epigallocatechin** gallate and
epicatechin gallate. The **catechin** is used to prevent a nasty smell
from DHA and EPA. The **catechin** is used in 0.01-0.20 w/w %, esp.
0.1-0.5 w/w % to the fats and oils. In order to enhance dispersibility,
there may be added fatty acid glycerides, propylene glycol fatty acid
esters or sucrose fatty acid esters.

USE/ADVANTAGE - The chocolate exhibits anti-**thrombosis** and anti-
atherosclerosis activity and is stable to oxidation. The flavour and
taste remain unchanged in the chocolate.

In an example, white chocolate was prepared from powdered sugar
(38 parts), powdered milk (32 parts), cacao butter (28 parts) and fish
oil (2 parts) containing **catechins** which contain EPA in 7 w/w % and
DHA in 14 w/w % and lecitin.

Dwg.0/0|

DE- <TITLE TERMS> CHOCOLATE; COMPOSITION; EFFECT; **THROMBOSIS** ;

ATHEROSCLEROSIS ; CONTAIN; FAT; EICOSA; PENTA; ENOIC; ACID; DOCOSA;
HEXA; ENOIC; ACID; **CATECHIN** |

DC- B05; D13; E17|

IC- <MAIN> A23G-001/00|

IC- <ADDITIONAL> A23L-001/30; A61K-035/78|

MC- <CPI> B06-A01; B10-C04E; B12-H02; D03-E07; E10-C04L2|

FS- CPI||

10/4/31

DIALOG(R) File 351:Derwent WPI

(c) 2001 Derwent Info Ltd. All rts. reserv.

AA- 1993-375304/199347 |

XR- <XRAM> C93-166881|

TI- Buccal compsn. for preventing dental caries and gingival diseases -
contains Sanggenon C which exhibits antiinflammatory activity, used in
tooth paste|

PA- PACIFIC CHEM CO LTD (PACI-N)|

AU- <INVENTORS> LEE H; PARK W|

NC- 001|

NP- 001|

PN- KR 9302725 B 19930409 KR 9010141 A 19900705 199347 B|

AN- <LOCAL> KR 9010141 A 19900705|

AN- <PR> KR 9010141 A 19900705|

FD- KR 9302725 B A61K-007/16|

AB- <BASIC> KR 9302725 B

The compsn. contg. 0.01-0.5 wt.% of Sanggenon C is used for

BEST AVAILABLE COPY